MPN-384 A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients With Myeloid/Lymphoid Neoplasms With Fibroblast Growth Factor Receptor 1 (FGFR1) Gene Rearrangement

Autor: Vannucchi, Alessandro M., Patel, Jay L., Shomali, William E., George, Tracy I., Reiter, Andreas, Rambaldi, Alessandro, Oh, Stephen, Usuki, Kensuke, Harrison, Claire N., Luisa Veronese, Maria, Gilmartin, Aidan, Zhen, Huiling, Verstovsek, Srdan, Oliveira, Natalia, Gotlib, Jason, Kiladjian, Jean-Jacques
Zdroj: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S430-S431
Databáze: ScienceDirect
Externí odkaz: